Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 10
Submit an article Journal homepage
375
Views
9
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis

Raimundo Fernando BezaresDepartment of Hematology, Hospital General de Agudos Dr T Alvarez, Buenos Aires, Argentina
,
German StemelinDepartment of Hematology, Hospital Británico, Buenos Aires, Argentina
,
Alicia DiazDepartment of Hematology, Hospital General de Agudos Dr T Alvarez, Buenos Aires, Argentina
,
Daniel ArgentieriDepartment of Hematology, Centro Sanatorio Junin, Junin, Argentina
,
Emilio Lanari ZubiaurDepartment of Hematology, Hospital Jose R Vidal, Corrientes, Argentina
,
Guy GarayDepartment of Hemotherapy, CEMIC, Buenos Aires, Argentina
,
Miguel BartomioliDepartment of Hematology, Hospital Privado del Sur, Bahia Blanca, Argentina
,
Ricardo RyserDepartment of Hematology, Sanatorio del Salvador, Cordoba, Argentina
&
Gustavo MiloneDepartment of Hemotherapy and Transplant, Fundaleu, Buenos Aires, ArgentinaCorrespondence[email protected]
 show all
Pages 1936-1941 | Received 27 Feb 2011, Accepted 26 Apr 2011, Published online: 30 Jun 2011

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Loretta J Nastoupil, Rajni Sinha & Christopher R Flowers. (2013) The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Review of Anticancer Therapy 13:9, pages 1089-1108.
Read now
Carmen Tur & Xavier Montalban. (2012) Subcutaneous alemtuzumab for multiple sclerosis. Expert Review of Clinical Immunology 8:5, pages 423-426.
Read now
Giuseppe Gritti, Gianluigi Reda, Francesco Maura, Alfonso Piciocchi, Luca Baldini, Stefano Molica, Antonino Neri & Agostino Cortelezzi. (2012) Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 53:3, pages 424-429.
Read now
Tamar Tadmor. (2011) Alemtuzumab (Campath-1H) for chronic lymphocytic leukemia: a drug in search of its optimal schedule. Leukemia & Lymphoma 52:10, pages 1831-1833.
Read now

Articles from other publishers (5)

Mariarita Sciumè, Daniele Vincenti, Gianluigi Reda, Nicola Orofino, Ramona Cassin, Diana Giannarelli, Gianluca Gaidano, Davide Rossi & Agostino Cortelezzi. (2015) Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience. American Journal of Hematology 90:11, pages 970-974.
Crossref
M. Fiegl, R. Stauder, M. Steurer, M. Mian, G. Hopfinger, Y. Brychtova, C. Skrabs, A. Zabernigg, F. Schmid, F. Haslbaur, G. Winder, A. Walder, A. Lang, D. Voskova, R. Greil, J. Mayer & G. Gastl. (2013) Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology 93:2, pages 267-277.
Crossref
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
Jai S Perumal, Farng Foo, Perry Cook & Omar Khan. (2012) Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Multiple Sclerosis Journal 18:8, pages 1197-1199.
Crossref
Agostino Cortelezzi, Giuseppe Gritti, Luca Laurenti, Antonio Cuneo, Stefania Ciolli, Nicola Di Renzo, Pellegrino Musto, Francesca R. Mauro, Nicola Cascavilla, Lorenzo Falchi, Francesco Zallio, Vincenzo Callea, Francesco Maura, Sara Martinelli, Alfonso Piciocchi, Gianluigi Reda & Robin Foà. (2012) An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. British Journal of Haematology 156:4, pages 481-489.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.